Floatz logo

Yttrium-90

Liver Cancer (Locally Advanced or Metastatic)

Niek WijnenradiopharmaceuticalPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Liver Cancer (Locally Advanced or Metastatic) cohort.

Asset / SponsorPhaseRating
Giapreza
Niek Wijnen
Phase 2CCC
Autologous Immune Cells
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
Phase 1/2CC
Daunorubicin
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
Phase 1/2CC
Cytosin-Arabinosid
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
Phase 1/2CC
sh009
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 1CC

Same molecule, other indications

Yttrium-90 is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →
Colorectal Carcinoma Metastatic in the LiverDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →